Home Conferences Contact Us Continuing Education Jobs Weekly News Archives Readership Profile

Monthly News Archives Pharmacy Awards Search Site Search Magazine Archives Submit a Classified Advertisement



15 February 2002 News Update


The British Health Department is considering a risk-sharing funding deal with manufacturers of multiple sclerosis (MS) treatments.

The UK National Institute for Clinical Excellence (NICE) has advised that betaferon and glatiramer should not be eligible for government funding because the potential benefit does not justify the cost.

A risk-sharing plan may provide more cost-effective for patients.
One option is to fund betaferon for relapsing-remitting MS patients, according to a report in The Pharmaceutical Journal. These patients would then be assessed to see if the drug was working, and if so, funding would continue.

If patients did not benefit from their treatment, payments to the drug company would be gradually discontinued.

Back to welcome page

Back to news archives


Complete this month's questionnaire to qualify for extra Continuing Education credits. Click here
For the answers to last month's quiz click here.


Click here to find out who the winners are for the Pharmacy Today/Zuellig Pharma Pharmacy Awards 2002. Also view and purchase photos of the Awards.


For the leading stories in our latest issue of Pharmacy Today magazine visit our welcome page.


To subscribe to Pharmacy Today, or to purchase The Beauty Manual or The Pharmacy Healthcare Handbook click here.

Job vacancies, items for sale, business opportunities and more.
Updated weekly.
click here.

Consumer Health Information

New Zealand Doctor Online